Fierce Pharma7d
Paratek acquires Optinose, rhinosinusitis spray Xhance in deal worth up to $330M
In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...
Emergent BioSolutions: I See Further Downside Ahead In This Value Trap
Emergent BioSolutions struggles with declining revenues, rising competition, and weak growth prospects. Read why I rate EBS ...
'I took a Barbie nasal spray and felt like I was drowning inside my body'
After being told about nasal sprays by a friend to help achieve a golden tan, Edith Eagle was left hospitalised on holiday ...
GlobalData on MSN6d
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease
In January, 2025, J&J’s nasal spray Spravato secured a label expansion from the FDA for use as a single agent in adults with ...
EMS17d
Nalmefene vs. Naloxone: Opioid-reversal drug research
What you need to know about opioid overdose reversal drug nalmefene’s risks, effectiveness and clinical concerns ...
Medical Dialogues8d
FDA Approves Needle-Free Allergy Treatment for Kids
The US Food and Drug Administration (FDA) has approved Neffy, a nasal spray for treating severe allergic reactions in ...
Endpoints News7d
Paratek boosts com­mer­cial port­fo­lio in move to buy Opti­nose and its nasal spray
Paratek Pharmaceuticals to acquire Optinose and its nasal drug-device Xhance for up to $330M, expanding beyond antibiotics ...